AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01114958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Thiosulfate
Description: Cisplatin (150 mg/m\^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m\^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m\^2).
Study NCT02002806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Injection
Description: Celiac plexus neurolysis by alcohol injection
Study NCT02002806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Study NCT00216099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Study NCT00216099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
Study NCT00216099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
Study NCT04053088 — intervention group
Intervention type: DEVICE
Intervention: INSPIRIS RESILIA Aortic Valve™
Description: Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
Study NCT01390116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aged garlic extract
Description: 2 aged garlic extract capsules taken twice daily
Study NCT03301103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTM202
Description: PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
Study NCT03164161 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold pressor test
Description: Described before.
Study NCT05535491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and Research Hospital
Description: breathing exercise
Study NCT03703297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)
Study NCT03703297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous infusion)
Study NCT03703297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV (intravenous infusion)
Study NCT03703297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (intravenous infusion)
Study NCT01720563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus polysaccharides 500 mg
Description: PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
Study NCT01720563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
Study NCT01720563 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks
Study NCT01720563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks
Study NCT02211898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNS003
Study NCT04358354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150 mg/m2
Study NCT04358354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2
Study NCT04358354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2
Study NCT04358354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
Study NCT04358354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
Study NCT00626418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aplindore
Description: Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
Study NCT00626418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT00628862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler® 4.5mg
Description: 4.5 mg inhaled twice daily
Study NCT00628862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler® 9 mg
Description: 9 mg inhaled twice daily
Study NCT00628862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Turbuhaler® placebo
Description: placebo inhaled twice daily
Study NCT03689699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
Study NCT04437888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
Study NCT04437888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
Study NCT03689699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
Study NCT03689699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
Study NCT04635358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Setting up hypnosis sessions
Study NCT04635358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: Setting up psychological support
Study NCT04635358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrional support
Description: Setting up nutritional support
Study NCT04668742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DYNAtraq
Description: Tracheostomy alignment with DYNAtraq
Study NCT02298140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminders
Description: Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
Study NCT01326715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mangafodipir (Teslascan)
Description: gadolinium enhancement on contrast enhanced brain MRI.
Study NCT01942707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominoplasty with Scarpa's Fascia
Description: During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
Study NCT01942707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominoplasty without Scarpa´s Facia
Description: During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
Study NCT00708032 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles
Study NCT00708032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A soft contact lenses
Description: narafilcon A daily disposable contact lenses
Study NCT01131494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor exercises for swallowing, breathing and phonation
Description: This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
Study NCT00190216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic stimulator
Study NCT04480827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 600mg, single dose
Description: Aramchol free acid tablet 600mg, single dose
Study NCT04480827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 300mg, bid
Description: Aramchol acid tablet 300mg, bid for 12 days
Study NCT03824262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HICO-VARIOTHERM 550
Description: Warming during perioperative period.
Study NCT03824262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mistral-Air Plus forced air warming device
Description: Warming during perioperative period.
Study NCT03824262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mistral-Air Plus forced air warming device
Description: Warming during perioperative period.
Study NCT02281318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
Study NCT02278718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NexoBrid
Description: NexoBrid is an enzymatic debriding agent for Eschar Removal.
Study NCT02278718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Surgical or Non-Surgical methods for Eschar Removal
Study NCT03164161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: β-endorphins evaluation in saliva
Description: Described before.
Study NCT03164161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: β-endorphins evaluation in blood plasma
Description: Described before.
Study NCT01605097 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR interstitial brachytherapy
Description: 2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
Study NCT00773188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv or 15mg/kg iv every 3 weeks
Study NCT00773188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75mg/m2 iv according to a standard chemotherapy treatment protocol
Study NCT00773188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 15mg/m2 iv according to a standard chemotherapy treatment protocol
Study NCT00502918 — intervention group
Intervention type: DEVICE
Intervention: CLM - HA Continuous Monitoring System Heart Application
Study NCT02143882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluenz
Description: Live attenuated influenza vaccine
Study NCT02876731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET-CT
Description: NaF PET-CT
Study NCT02876731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: DWMRI
Study NCT02281318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% sodium chloride solution
Study NCT02281318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
Study NCT02281318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
Study NCT01698255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE
Study NCT01698255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Psychotherapy
Study NCT03784768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar Vibration Group
Description: Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
Study NCT03784768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
Study NCT01980069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
Study NCT01980069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
Study NCT02804516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the nurse did early mobilization
Description: the nurses know and do what is the early mobilization in ICU
Study NCT02804516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the nurse do not do early mobilization
Description: the nurses do not know and do what is the early mobilization in ICU
Study NCT04376502 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: Radiation therapy for all subjects will consist of treating one tumor of the treating physician's preference (40 Gray (Gy) in 5 fractions), and after a 1-week interval during which ICI is continued alone, radiation therapy will be given to a second and separate tumor (30 Gy in 5 fractions).
Study NCT04442724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiducial marker placement
Description: placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection
Study NCT04442724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI (mpMRI)
Description: In this study, mp-MRI is defined as MRI that includes T1 \& T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.
Study NCT00441025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Study NCT03825133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
Study NCT01390116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AGE
Description: encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education: One-on-one visit
Description: The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
Study NCT03825133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukocyte Rich Platelet Rich Plasma
Description: Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee
Study NCT03825133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge planning: Assessment of barriers to discharge
Description: Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
Study NCT02490189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
Study NCT02490189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Group Therapy
Description: Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
Study NCT02688439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sciatic Nerve block
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation: Patient medication review
Description: The navigator will review the patient's medications with him/her prior to discharge.
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Appointment before discharge: Additional measure to ensure awareness of next clinic visit
Description: Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transition coach
Description: The navigator will assist with coordination of care and tracking follow-up appointments and tests.
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered discharge instructions: Enhanced
Description: Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology
Description: Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline.
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timely follow-up: Barriers to clinic follow-up visits will be discussed
Description: Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timely PCP communication
Description: The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up telephone call
Description: Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.